| abstract |
Methods and compositions for modifying type I IFN signaling pathways in a subject comprising the administration a cationic lipid to the subject are provided. The cationic lipids comprise l,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-l-(2,3-dioleoyloxy)-propyl- Ν, Ν, Ν-trimethyl ammonium chloride (DOTMA), l,2-dioleoyl-sn-glycero-3- ethylphosphocholine (DOEPC), enantiomers and combinations thereof. The compositions may further comprise one or more antigenic components, wherein such components are autologous or nonautologous. |